Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAP3K11 | Q16584 | 14/20 | 1.00 |
| ▸ | MAP3K9 | P80192 | 12/20 | 1.00 |
| ▸ | MAP3K10 | Q02779 | 8/20 | 1.00 |
| ▸ | KDR | P35968 | 4/20 | 0.83 |
| ▸ | FLT1 | P17948 | 1/20 | 0.83 |
| ▸ | FLT4 | P35916 | 1/20 | 0.83 |
| ▸ | DLK1 | P80370 | 1/20 | 0.83 |
| ▸ | NTRK1 | P04629 | 8/20 | 0.82 |
| ▸ | PRKCQ | Q04759 | 4/20 | 0.73 |
| ▸ | PRKD3 | O94806 | 3/20 | 0.73 |
| ▸ | PRKCG | P05129 | 3/20 | 0.73 |
| ▸ | PRKCB | P05771 | 3/20 | 0.73 |
| ▸ | PRKCA | P17252 | 3/20 | 0.73 |
| ▸ | PRKCH | P24723 | 3/20 | 0.73 |
| ▸ | PRKCI | P41743 | 3/20 | 0.73 |
| ▸ | PRKCE | Q02156 | 3/20 | 0.73 |
| ▸ | PRKCZ | Q05513 | 3/20 | 0.73 |
| ▸ | PRKCD | Q05655 | 3/20 | 0.73 |
| ▸ | PRKD1 | Q15139 | 3/20 | 0.73 |
| ▸ | MYLK | Q15746 | 3/20 | 0.73 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15289975 | 1.00 | MAP3K11 (1.00) | MAP3K11MAP3K9MAP3K10KDRFLT1 | |
| Cep-1347 SCHEMBL12047710 | 0.91 | MAP3K11 (1.00) | MAP3K11MAP3K9MAP3K10KDRFLT1 | |
| Cep-1347 SCHEMBL8263437 | 0.91 | MAP3K11 (1.00) | MAP3K11MAP3K9MAP3K10KDRFLT1 | |
| Cep-1347 SCHEMBL29381680 | 0.91 | MAP3K11 (1.00) | MAP3K11MAP3K9MAP3K10KDRFLT1 | |
| Cep-1347 SCHEMBL30198505 | 0.91 | MAP3K11 (1.00) | MAP3K11MAP3K9MAP3K10KDRFLT1 | |
| SCHEMBL13142263 | 0.88 | MAP3K11 (0.93) | MAP3K11MAP3K9MAP3K10KDRFLT1 | |
| SCHEMBL13140134 | 0.88 | MAP3K11 (0.93) | MAP3K11MAP3K9MAP3K10KDRFLT1 | |
| SCHEMBL13169950 | 0.87 | MAP3K11 (0.83) | MAP3K11MAP3K9MAP3K10KDRFLT1 | |
| SCHEMBL13140084 | 0.87 | MAP3K11 (0.77) | MAP3K11MAP3K9MAP3K10KDRFLT1 | |
| SCHEMBL13179116 | 0.86 | MAP3K11 (0.78) | MAP3K11MAP3K9MAP3K10KDRFLT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 54 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12364681-B2 | Combined MAPK and NAMPT inhibition for treatment of neuron degeneration | THE JOHNS HOPKINS UNIVERSITY (US) | 2025-07-22 | — | — | US | claimed |
| US-20240398848-A1 | MLK-Regulated microRNAs in Angiogenesis and Tumor Development | UNIVERSITY OF MASSACHUSETTS | 2024-12-05 | — | — | US | claimed |
| US-20220218662-A1 | COMBINED MAPK AND NAMPT INHIBITION FOR TREATMENT OF NEURON DEGENERATION | THE JOHNS HOPKINS UNIVERSITY | 2022-07-14 | — | — | US | claimed |
| US-20260144674-A1 | Apparatus and Methods for Drug Delivery Using Microneedles | CLEARSIDE BIOMEDICAL, INC. (US) | 2026-05-28 | — | — | US | disclosed |
| EP-4709405-A2 | FLUORESCEIN-LABELED NERVE TARGETING PEPTIDE FORMULATIONS AND RELATED METHODS | Alume Biosciences, Inc. (US) | 2026-03-18 | — | — | EP | disclosed |
| US-12533425-B2 | Methods and systems using peptides for targeting and mapping human nerves in image guided surgery, diagnostics and therapeutic delivery | ALUME BIOSCIENCES, INC. (US) | 2026-01-27 | — | — | US | disclosed |
| US-20250345206-A1 | APPARATUS AND METHODS FOR OCULAR INJECTION | CLEARSIDE BIOMEDICAL, INC. (US) | 2025-11-13 | — | — | US | disclosed |
| US-12364681-B2 | Combined MAPK and NAMPT inhibition for treatment of neuron degeneration | THE JOHNS HOPKINS UNIVERSITY (US) | 2025-07-22 | — | — | US | disclosed |
| US-12350261-B2 | Methods and devices for the treatment of ocular diseases in human subjects | CLEARSIDE BIOMEDICAL, INC. (US) | 2025-07-08 | — | — | US | disclosed |
| US-20250186253-A1 | DEVICES AND METHODS FOR ADJUSTING THE INSERTION DEPTH OF A NEEDLE FOR MEDICAMENT DELIVERY | CLEARSIDE BIOMEDICAL, INC. (US) | 2025-06-12 | — | — | US | disclosed |
| EP-4566672-A2 | METHODS FOR THE TREATMENT OF OCULAR DISEASE IN HUMAN SUBJECTS | Clearside Biomedical Inc. (US) | 2025-06-11 | — | — | EP | disclosed |
| US-20220280341-A1 | APPARATUS AND METHODS FOR DRUG DELIVERY USING MICRONEEDLES | CLEARSIDE ROYALTY LLC | 2022-09-08 | — | — | US | disclosed |
| EP-4041311-A1 | METHODS AND SYSTEMS USING PEPTIDES FOR TARGETING AND MAPPING HUMAN NERVES IN IMAGE GUIDED SURGERY, DIAGNOSTICS AND THERAPEUTIC DELIVERY | Alume Biosciences, Inc. (US) | 2022-08-17 | — | — | EP | disclosed |
| US-20220218662-A1 | COMBINED MAPK AND NAMPT INHIBITION FOR TREATMENT OF NEURON DEGENERATION | THE JOHNS HOPKINS UNIVERSITY | 2022-07-14 | — | — | US | disclosed |
| WO-2022120177-A1 | NERVE TARGETING PEPTIDES AND METHODS OF USE | ALUME BIOSCIENCES, INC. (US) | 2022-06-09 | — | — | WO | disclosed |
| WO-2022076938-A1 | APPARATUS AND METHODS OF RETINAL INJECTION | CLEARSIDE BIOMEDICAL, INC. (US) | 2022-04-14 | — | — | WO | disclosed |
| US-11299515-B2 | Optimized peptides for targeting human nerves and their use in image guided surgery, diagnostics and therapeutic | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2022-04-12 | — | — | US | disclosed |
| US-20220090086-A1 | IDENTIFICATION OF MOLECULAR PATHWAYS AND METHODS OF USE THEREOF FOR TREATING RETINAL NEURODEGENERATION AND OTHER NEURODEGENERATIVE DISORDERS | THE JOHNS HOPKINS UNIVERSITY | 2022-03-24 | — | — | US | disclosed |
| US-11246940-B2 | Peptides whose uptake in cells is controllable | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2022-02-15 | — | — | US | disclosed |
| CN-110177527-B | Device and method for adjusting insertion depth of needle for medicament delivery | 科尼尔赛德生物医学公司 | 2022-02-01 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260144674-A1 | Apparatus and Methods for Drug Delivery Using Microneedles | PROKR2, SLC10A2, GLP1R | MAP3K11 1133/4885MAP3K9 776/4885MAP3K10 1064/4885 |
| US-20220090086-A1 | IDENTIFICATION OF MOLECULAR PATHWAYS AND METHODS OF USE THEREOF FOR TREATING RETINAL NEURODEGENERATION AND OTHER NEURODEGENERATIVE DISORDERS | ALDH1A2, NLN, CLN6 | MAP3K11 461/4885MAP3K9 467/4885MAP3K10 262/4885 |
| US-12533425-B2 | Methods and systems using peptides for targeting and mapping human nerves in image guided surgery, diagnostics and therapeutic delivery | NGLY1, VGF, GAP43 | MAP3K11 1044/4885MAP3K9 1481/4885MAP3K10 1407/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.